Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-11-2019 | Ovarian Cancer | Original Article – Cancer Research

Outcome in serous ovarian cancer is not associated with LATS expression

Authors: Céline Montavon, Gregor R. Stricker, Andreas Schoetzau, Viola Heinzelmann-Schwarz, Francis Jacob, André Fedier

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/2019

Abstract

Background

Large tumor suppressor (LATS) proteins are putative tumor suppressors and poorly expressed associated with poor outcome in many cancers. A recent immunohistochemistry study showed that LATS protein expression correlated with poor outcome in serous ovarian cancer.

Materials and methods

We analyzed LATS expression in various ovarian cancer transcriptomic data sets and immunohistochemically assessed LATS protein expression in a Swiss ovarian tumor cohort. Results were compared to clinicopathological characteristics and outcome. We also compared LATS protein expression in serous ovarian cancer cell lines to their EMT status (Western blotting) and drug sensitivity (MTT assay).

Results

The analysis of 15 different transcriptomic data sets showed that LATS2 was associated with poorer outcome, while LATS1 was irrelevant (HR = 1.19 and HR = 1.00, respectively). The TCGA-RNASeqV2 data set showed that low LATS1 and LATS2 were associated with better survival in serous ovarian carcinoma. Despite heterogeneity among the different data sets, LATS expression is not an indicator of survival in serous ovarian cancer and LATS2 expression may even be tumorigenic. LATS expression was neither associated with survival nor with the stage and grade in the Swiss cohort. It was low in cystadenoma, intermediate in carcinoma, and high in borderline tumors and was higher in serous than mucinous ovarian carcinoma. LATS protein expression extent was comparable in epithelial-, intermediate-, and mesenchymal-type ovarian cancer cells and was not associated with drug sensitivity.

Conclusion

These results are largely incompatible with a tumor-suppressive function of LATS in ovarian cancer, and LATS protein level is also not an indicator for drug sensitivity and EMT status of ovarian cancer cells.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA et al (2015) Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15:668–679CrossRef

Furth N, Aylon Y (2017) The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ 24:1488–1501CrossRef

Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I, Wang XV, Ahmadifar M, Birrer MJ, Parmigiani G et al (2013) CuratedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford) 2013:bat013CrossRef

Jacob F, Ukegjini K, Nixdorf S, Ford CE, Olivier J, Caduff R, Scurry JP, Guertler R, Hornung D, Mueller R et al (2012) Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients. PLoS One 7:e31885CrossRef

Jacob F, Alam S, Konantz M, Liang CY, Kohler RS, Everest-Dass AV, Huang YL, Rimmer N, Fedier A, Schötzau A et al (2018) Transition of mesenchymal and epithelial cancer cells depends on α1–4 galactosyltransferase-mediated glycosphingolipids. Cancer Res 78:2952–2965CrossRef

Janse van Rensburg HJ, Yang X (2016) The roles of the Hippo pathway in cancer metastasis. Cell Signal 28:1761–1772CrossRef

Jiménez-Velasco A, Román-Gómez J, Agirre X, Barrios M, Navarro G, Vázquez I, Prósper F, Torres A, Heiniger A (2005) Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia 19:2347–2350CrossRef

Kawahara M, Hori T, Chonabayashi K, Oka T, Sudol M, Uchiyama T (2008) Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood 112:3856–3866CrossRef

Kohler RS, Kettelhack H, Knipprath-Mészaros AM, Fedier A, Schoetzau A, Jacob F, Heinzelmann-Schwarz V (2017) MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells. Gynecol Oncol 145:159–166CrossRef

Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL (2008) TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 28:2426–2436CrossRef

Lin XY, Zhang XP, Wu JH, Qiu XS, Wang EH (2014) Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer. Tumour Biol 35:6435–6443CrossRef

Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC (1988) Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 48:5713–5716PubMed

Meng Z, Moroishi T, Guan KL (2016) Mechanisms of Hippo pathway regulation. Genes Dev 30:1–17CrossRef

Morinaga N, Shitara Y, Yanagita Y, Koida T, Kimura M, Asao T, Kimijima I, Takenoshita S, Hirota T, Saya H et al (2000) Molecular analysis of the h-warts/LATS1 gene in human breast cancer. Int J Oncol 17:1125–1129PubMed

Moroishi T, Hansen CG, Guan KL (2015) The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 15:73–79CrossRef

Nozaki M, Yabuta N, Fukuzawa M, Mukai S, Okamoto A, Sasakura T, Fukushima K, Naito Y, Longmore GD, Nojima H (2019) LATS1/2 kinases trigger self-renewal of cancer stem cells in aggressive oral cancer. Oncotarget 10:1014–1030CrossRef

Ozols RF (2006) Challenges for chemotherapy in ovarian cancer. Ann Oncol 17(Suppl 5):v181–v187CrossRef

Plouffe SW, Hong AW, Guan KL (2015) Disease implications of the Hippo/YAP pathway. Trends Mol Med 21:212–222CrossRef

Son MW, Song GJ, Jang SH, Hong SA, Oh MH, Lee JH, Baek MJ, Lee MS (2017) Clinicopathological significance of large tumor suppressor (LATS) expression in gastric cancer. Gastric Cancer 17:363–373CrossRef

Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S (2005) Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 11:1380–1385CrossRef

Takahashi Y, Miyoshi Y, Morimoto K, Taguchi T, Tamaki Y, Noguchi S (2007) Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers. J Cancer Res Clin Oncol 133:501–509CrossRef

Visser S, Yang X (2010) LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 9:3892–3903CrossRef

Xu B, Sun D, Wang Z, Weng H, Wu D, Zhang X, Zhou Y, Hu W (2015) Expression of LATS family proteins in ovarian tumors and its significance. Hum Pathol 46:858–867CrossRef

Yeung B, Khanal P, Mehta V, Trinkle-Mulcahy L, Yang X (2018) Identification of Cdk1-LATS-Pin1 as a novel signaling axis in anti-tubulin drug response of cancer cells. Mol Cancer Res 16:1035–1045CrossRef

Yoshiya N, Adachi S, Misawa Y, Yuzawa H, Honda T, Kanazawa K, Takeuchi S, Tanaka K (1989) Isolation of cisplatin-resistant subline from human ovarian cancer cell line and analysis of its cell-biological characteristics. Nihon Sanka Fujinka Gakkai Zasshi 41:7–14PubMed

Yu FX, Zhao B, Guan KL (2015) Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163:811–828CrossRef

Zanconato F, Cordenonsi M, Piccolo S (2016) YAP/TAZ at the roots of cancer. Cancer Cell 29:783–803CrossRef

Zhang Y, Hu CF, Chen J, Yan LX, Zeng YX, Shao JY (2010) LATS2 is de-methylated and overexpressed in nasopharyngeal carcinoma and predicts poor prognosis. BMC Cancer 10:538CrossRef

Zhang K, Rodriguez-Aznar E, Yabuta N, Owen RJ, Mingot JM, Nojima H, Nieto MA, Longmore GD (2012) Lats2 kinase potentiates Snail1 activity by promoting nuclear retention upon phosphorylation. EMBO J 31:29–43CrossRef

Title: Outcome in serous ovarian cancer is not associated with LATS expression
Authors: Céline Montavon
Gregor R. Stricker
Andreas Schoetzau
Viola Heinzelmann-Schwarz
Francis Jacob
André Fedier
Publication date: 01-11-2019
Publisher: Springer Berlin Heidelberg
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: Journal of Cancer Research and Clinical Oncology / Issue 11/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-03037-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Outcome in serous ovarian cancer is not associated with LATS expression

Abstract

Background

Materials and methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2019

Association between lymphovascular invasion and oncologic outcomes among upper urinary tract urothelial carcinoma patients who underwent radical nephroureterectomy

CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach

Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer

Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients

Active surveillance of low-risk papillary thyroid carcinoma: a promising strategy requiring additional evidence

Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page